


Why is PRV131 Needed

- Fast-growing tumors such as lung malignancies remain difficult to manage, even after patients receive surgery, radiation, and chemotherapy
- There is a high rate of local recurrence, with over 30% of patients dying due to local lung tumors
- Currently available therapies aren't "enough" to prevent tumors from growing back in a short period of time, and often make patients extremely sick with toxic side effects
- Ideal for treating patient population that can not tolerate systemic anticancer treatments. This includes children and the elderly.



Preclinical Proof of Concept?

PRV131 was studied in several animal models to ensure its safety, efficacy, and superiority to existing chemotherapy (cisplatin). The results of one study are shown below. Aggressive colon cancer (MC38) cells were implanted into mice and once tumors grew, they were treated with a single injection of PRV131 or solution cisplatin (standard chemotherapy). Mice were monitored for up to 60 days to assess safety (survival) and efficacy (tumor growth inhibition).



- 80% of PRV131 treated mice survived to day 60 post inoculation
- **No detectable tumor found in 60% of PRV131 treated mice \geq 38 days post treatment**
- PRV131 400 μ g has dramatically improved efficacy and survival than all control groups

Privo^otechnologies.

Tough On Cancer, Easy On Patients



PRV131 – Sustained-Released, Localized, Highly Concentrated Intratumoral Cisplatin Injectable

What is PRV131?

Welcome to the future of targeted cancer therapy. PRV131 is a groundbreaking intratumoral injectable treatment that will transform the landscape of cancer care for solid tumors. PRV131 is a preclinical asset with proven efficacy and safety in several animal models. Key highlights include:



- **A single, local injection controls and shrinks tumors for >28 days**
- Nanotechnology allows for super-concentrated chemotherapy to be delivered and retained in the tumor, avoiding systemic exposure

What's next?

- Privo is fundraising to initiate a clinical trial with PRV131 in 2024

Why is PRV131 Needed & How Does it work?

PRV-131 is a novel system comprising a unique formulation, including nanoparticles which non-covalently interact with payloads to increase drug dispersion and diffusion when dosed intratumorally (IT) into solid tumors. Privo's proprietary matrix is developed to stabilize the injectable and improve greater tumor growth inhibition and even drug distribution throughout the tumor. These properties have shown to significantly improve survival in in-vivo tumor models compared to the same drugs in free form.


Immune Response

In addition, PRV-131 treatment increased immune infiltrating cells in injected tumors with 50% to 60% of the animals having complete responses and developing systemic immunity to cancer. The multitude of Privo's preclinical studies demonstrate a novel, local treatment approach for cancer that maximizes tumor destruction via two-punch attack with chemotherapy and immunomodulation. This is how Privo is "Tough on Cancer". PRV131 is an IT injection which minimizes systemic toxicity and "Easy on Patients". This defense and offense goes on while stimulating adaptive immunity.



NOTE: Privo has extensively tested PRV131 injection via broncoscopes, endoscopes and simple syringes with ZERO failure in injectability.

PRV131 and PRV111 are derivative of Privo's platform technology. This technology has been studied and its efficacy and safety was tested in human trial, successfully meeting all the endpoints ([NCT03502148](https://clinicaltrials.gov/ct2/show/study/NCT03502148)).



PRV111 therapy causing tumor control, tumor shrinkage and frequently tumor regression causing with significant immune response

